NABL:NYSEN-able, Inc. Analysis
Data as of 2026-08-26 - not real-time
$3.75
Latest Price
9/10Risk
Risk Level: High
Executive Summary
The moving-average structure behind N-able, Inc. is neutral at $3.75, with no clear ordering between short and long averages. It has lost 16.9% over the past 30 days. With RSI at 47.4 the momentum picture is neutral, alongside a bearish MACD signal. Recent trading has carved out support near $2.98 and resistance around $5.25.
The shares look undervalued, trading on 8.7 times earnings below a sector average of 34.9. Analyst price targets sit 24.8% above the current price. Revenue is growing at 5.9% on a -1.0% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 153.8%, a beta of 0.76 and a maximum drawdown of 64.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
The shares look undervalued, trading on 8.7 times earnings below a sector average of 34.9. Analyst price targets sit 24.8% above the current price. Revenue is growing at 5.9% on a -1.0% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 153.8%, a beta of 0.76 and a maximum drawdown of 64.7%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 93 on the fear-greed composite.
The horizons line up on hold — conviction 1 out of 10.
Top Market Events
N-able Inc NABL delivers solid Q2 2026 results with 6% ARR growth, but lowers full-year guidance due to UEM and EDR...Conestoga Capital Advisors, an asset management company, released its second-quarter 2026 investor letter.Yahoo Finance16dN-able, Inc. NABL Q2 FY2026 earnings call transcriptN-Able delivered Q2 2026 ARR of $544M +6% YoY and...
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 1/10
Key Factors
- Trading below the 200-day average of 5.24
- MACD momentum is negative
- 30-day price change of -16.9%
Medium Term
1–3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 8.7 versus sector average of 34.9
- Trading below the 200-day average of 5.24
- Analyst targets imply +24.8% versus the current price
Long Term
> 3 yearsNeutral
Model confidence: 1/10
Key Factors
- P/E of 8.7 versus sector average of 34.9
- Negative profit margin of -1.0%
- Analyst targets imply +24.8% versus the current price
Key Metrics & Analysis
Financial Health
Revenue Growth5.90%
Profit Margin-0.96%
P/E Ratio8.7
ROE-0.63%
ROA2.06%
Debt/Equity54.25
P/B Ratio0.9
Op. Cash Flow$93.3M
Free Cash Flow$70.1M
Industry P/E34.9
Technical Analysis
TrendNeutral
RSI47.4
Support$2.98
Resistance$5.25
MA 20$4.00
MA 50$3.98
MA 200$5.24
MACDBearish
VolumeIncreasing
Fear & Greed Index93.39
Valuation
Fair Value$4.40
Target Price$4.68
Upside/Downside24.80%
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.76
Volatility153.78%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.